There were a few long reads that I’ll be re-reading over the weekend, including: New blood (at Fortune, by Roger Parloff @rparloff) This article profiles the blood diagnostics company, Theranos, and the founder, Elizabeth Holmes. While you will find the founder description interesting, I found myself drawn to the questions of business model, trade secrets and regulation.
What happens when you combine a crowdsourcing effort to identify active life science venture capital funds and add a couple of biotech entrepreneurs active in social media? In this case: a spreadsheet and a blog post. Crowdsourcing Data In the fall, there was a discussion on Twitter about the importance of life science entrepreneurs understanding
In August 2012, Luke Timmerman of Xconomy wrote about the hurt being caused to biotech clusters as they are losing anchor tenants. Luke mentions the acquisitions of Amylin Pharmaceuticals in San Diego by Bristol Myers Squibb and Human Genome Sciences in Washington DC by Glaxo Smith Kline. Acquisitions can be positive at times (e.g. providing
My personal curiosities include the intersection of technology and medicine (often referred to as health/healthcare/medical information technology, health 2.0, eHealth, etc.). Lately, I’ve been looking into what is happening in health IT around Madison* and found some interesting things. An Epic Connection? If you have an interest in Electronic Health Records (EHR), you have certainly
How can scientists successfully transition from academia to industry? This question has come to mind repeatedly in a variety of settings over the last six months or so. In response to this question, I propose that the pharma/biotech* industry step in to fill the gap between teaching people science, which academia does very well, and